ZNA
Welcome,         Profile    Billing    Logout  
 3 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Granacher, Nikki CP
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Calendar Jan 2024 - Dec 2024: Approval for myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Feb 2024 - Feb 2024: Exclusivity expiry in US
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

Checkmark Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Hourglass Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis
Checkmark Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
More
Recruiting
3
330
Europe, Canada, US, RoW
Selinexor, KPT-330, Placebo, Ruxolitinib
Karyopharm Therapeutics Inc
Myelofibrosis
09/25
03/28
Predictor2, NCT03887156: Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft

Recruiting
2/3
227
Europe
Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test
Assistance Publique - Hôpitaux de Paris, SATT, SNC Graft Versus Host Disease, Imagine Institute, Axonal-Biostatem, CERBA laboratory
Acute Myeloid Leukemia in Remission, Lymphoma in Remission, Non-progressive Myeloproliferative Syndrome, Myelodysplasia With Stable Blasts is Cell Number and < 10% of Blastocysts, Acute Leukemia Biphenotypic in Remission, Acute Lymphoblastic Leukemia
03/23
03/23
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Active, not recruiting
1/2
122
Europe, US, RoW
Vodobatinib (K0706) capsules
Sun Pharma Advanced Research Company Limited
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
08/26
08/26
Goudman, Lisa
SILENT 1, NCT04703452: poSt Covid-19 Infection centraL sENsitisaTion

Recruiting
N/A
100
Europe
Indicators of central sensitisation
Universitair Ziekenhuis Brussel
Covid19
01/22
01/22
SILENT 2, NCT04701892: poSt Covid-19 Infection centraL Sensitisation 2

Recruiting
N/A
200
Europe
Indicators of central sensitisation
Universitair Ziekenhuis Brussel
Covid19
01/23
01/23
DYSCO, NCT04716465: Dysautonomia in Patients Post COVID-19 Infection

Recruiting
N/A
200
Europe
Dysautonomia
Moens Maarten
Covid19
01/23
01/23
TRADITION, NCT05169047: Subthreshold SCS or BMT

Recruiting
N/A
114
Europe
Best Medical Treatment, Subthreshold Spinal Cord Stimulation
Moens Maarten
Failed Back Surgery Syndrome
01/24
08/24
DETECT, NCT05068011: Differential Target Multiplexed Spinal Cord Stimulation

Recruiting
N/A
250
Europe
Spinal Cord Stimulation
Moens Maarten
Failed Back Surgery Syndrome, Persistent Spinal Pain Syndrome Type 2
08/26
08/26
Maarevoet, Marie
EPCORE DLBCL-3, NCT05660967: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Recruiting
2
180
Europe, Japan, US, RoW
Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/26
03/27

Download Options